These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 19157628)

  • 1. Industry views of biosimilar development in Japan.
    Horikawa H; Tsubouchi M; Kawakami K
    Health Policy; 2009 Jul; 91(2):189-94. PubMed ID: 19157628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory guidelines for biosimilars in Malaysia.
    Abas A
    Biologicals; 2011 Sep; 39(5):339-42. PubMed ID: 21784655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars: current status and future directions.
    Roger SD
    Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A biosimilar industry view on the implementation of the WHO guidelines on evaluating similar biotherapeutic products.
    Schiestl M
    Biologicals; 2011 Sep; 39(5):297-9. PubMed ID: 21784654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of biopharmaceuticals.
    Kessler M; Goldsmith D; Schellekens H
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v9-12. PubMed ID: 16959792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manufacturing of biopharmaceuticals and implications for biosimilars.
    Wurm FM
    Kidney Blood Press Res; 2007; 30 Suppl 1():6-8. PubMed ID: 17726336
    [No Abstract]   [Full Text] [Related]  

  • 7. Concept of biosimilar products in Jordan.
    Haddadin RD
    Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars and non-innovator biotherapeutics in India: an overview of the current situation.
    Malhotra H
    Biologicals; 2011 Sep; 39(5):321-4. PubMed ID: 21784652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars: opportunity or cause for concern?
    Roger SD; Mikhail A
    J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative testing and pharmacovigilance of biosimilars.
    Locatelli F; Roger S
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v13-6. PubMed ID: 16959789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The regulatory framework for similar biotherapeutic products in Cuba.
    Hechavarría Núñez Y; Pérez Massipe RO; Orta Hernández SD; Muñoz LM; Jacobo Casanueva OL; Pérez Rodríguez V; Domínguez Morales RB; Pérez Cristiá RB
    Biologicals; 2011 Sep; 39(5):317-20. PubMed ID: 21930393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations and requirements for the design of bioanalytical testing used in comparability studies for biosimilar drug development.
    Cai XY; Gouty D; Baughman S; Ramakrishnan M; Cullen C
    Bioanalysis; 2011 Mar; 3(5):535-40. PubMed ID: 21388266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharma industry in India.
    Sundaram VM
    Drug News Perspect; 2008; 21(1):59-63. PubMed ID: 18301810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An unofficial legislative history of the Biologics Price Competition and Innovation Act of 2009.
    Carver KH; Elikan J; Lietzan E
    Food Drug Law J; 2010; 65(4):671-818, ii. PubMed ID: 24479247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant drug development, regulation, and commercialization: an Indian industry perspective.
    Sahoo N; Manchikanti P
    BioDrugs; 2011 Apr; 25(2):105-13. PubMed ID: 21230010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current regulatory and scientific considerations for approving biosimilars in Iran.
    Hadavand N; Valadkhani M; Zarbakhsh A
    Biologicals; 2011 Sep; 39(5):325-7. PubMed ID: 21873077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of the clinical application of regenerative medicine products in Japan.
    Tsubouchi M; Matsui S; Banno Y; Kurokawa K; Kawakami K
    Health Policy; 2008 Oct; 88(1):62-72. PubMed ID: 18395290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global regulatory standards for the approval of biosimilars.
    Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
    Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Manufacturing, regulatory and commercial challenges of biopharmaceuticals production: a Finnish perspective.
    Närhi M; Nordström K
    Eur J Pharm Biopharm; 2005 Apr; 59(3):397-405. PubMed ID: 15760720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Similarity of biotechnology-derived drugs: regulatory framework and specificity].
    Prugnaud JL
    Ann Pharm Fr; 2008 Aug; 66(4):206-11. PubMed ID: 18847566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.